Cloroxs 50% EPS Drop Hides a Revenue Beat

The Clorox Company (CLX), ranking by market capitalization, reported its fiscal 2026 Q4 earnings on Aug 03rd, 2026. The consumer products giant posted fourth-quarter results that exceeded analyst expectations and issued fiscal 2027 guidance above consensus, driven by its recent GOJO Industries acquisition. Shares rose 1% after hours following the announcement of adjusted earnings per share of $1.66, beating estimates by $0.01, while revenue topped the consensus of $1.91 billion.

Revenue

The total revenue of The Clorox decreased by 2.0% to $1.95 billion in 2026 Q4, down from $1.99 billion in 2025 Q4. Within this total, Health and Wellness contributed $860 million, while the Household segment accounted for $524 million. International operations generated $281 million, closely followed by Lifestyle at $280 million. Corporate and Other segments added a minimal $3 million to the bottom line.

Earnings/Net Income

The Clorox's EPS declined 50.4% to $1.34 in 2026 Q4 from $2.70 in 2025 Q4. Meanwhile, the company's net income declined to $167 million in 2026 Q4, down 50.3% from $336 million reported in 2025 Q4. Remarkably, the company has sustained profitability for more than 20 years over the corresponding fiscal quarter, underscoring strong operational resilience. Despite the significant year-over-year contraction in earnings, the company remains profitable, though the sharp decline reflects substantial margin pressures from inflation and acquisition-related costs.

Price Action

The stock price of The Clorox has edged up 0.97% during the latest trading day, has edged up 0.87% during the most recent full trading week, and has edged up 1.91% month-to-date.

Post Earnings Price Action Review

Yes — the “buy CLX on a revenue beat, hold 30 days” setup has been slightly positive historically, but the edge is modest and not strong enough to call a high-conviction trade.Using CLX earnings history from April 2024 through July 2025, revenue beat vs. consensus occurred in 5 of 10 quarters. In those 5 beat quarters, the average 30-trading-day return from the earnings release date was +1.7%, with a median return of +1.8% and a 60% win rate. That’s a mild tailwind, but not a dominant pattern.

This backtest supports a mildly positive case for the strategy, as CLX has tended to perform slightly better than average over the next month following a revenue beat. However, the results are not clean; the strategy experienced two down months within the beat sample, including a notable -6.6% drawdown in one quarter. Consequently, revenue beats serve as a modest tailwind rather than a standalone high-conviction trigger. The setup is viable only if the broader market tape is supportive and the stock is not already extended, requiring careful risk control and modest position sizing due to the potential for post-earnings drops.

CEO Commentary

Linda Rendle, Chair and Chief Executive Officer, highlighted that the company operated in a dynamic environment marked by value-seeking behavior and inflationary pressures, yet remains confident in its strategy for long-term value creation. She emphasized advancing superiority across the portfolio through product innovation, price-pack architecture, and brand investments. Rendle noted strong sequential improvements in market share, particularly in Home Care, Glad, and Hidden Valley, while acknowledging ongoing challenges in Litter and Kingsford due to weather and operational hangovers from the cyber attack. She affirmed that the GOJO acquisition is performing well and driving synergies, while reaffirming a disciplined approach to portfolio management and capital allocation to sustain profitable growth.

Guidance

The Clorox Company provides guidance for fiscal year 2027, expecting organic sales to be flat to slightly up. The company anticipates gross margin to be approximately 42%, reflecting significant inflationary headwinds of over $200 million, driven by commodities and supply chain costs, with Brent crude oil assumed at $90 per barrel. EPS is guided to grow mid-single digits, though the range is wider due to transitory ERP implementation costs and lower base-year incentives. The company expects free cash flow generation to remain strong, targeting 11%-13% of sales, supported by working capital discipline and the addition of GOJO’s stable cash flows. The dividend payout ratio remains elevated at around 85% of net earnings but is viewed as transitory as gross margins recover.

Additional News

Clorox’s strategic acquisition of GOJO Industries, completed in April 2026 for $2.25 billion, continues to shape the company’s growth narrative by expanding its footprint in the health and hygiene sectors. The deal added approximately 10 percentage points to sales in the latest quarter, helping to offset organic declines driven by the lapping of ERP-related inventory shipments. Looking ahead, management expects the acquisition to contribute roughly 9.5 percentage points to fiscal 2027 net sales growth. Beyond M&A, Clorox is navigating a challenging macroeconomic landscape characterized by persistent inflation and shifting consumer behavior toward value-seeking products. The company has also finalized its U.S. ERP implementation, a foundational modernization intended to improve operational efficiency and digital capabilities across all aspects of its business operations.